Sign in Subscribe
Biotechnology industries

Procyon Biopharma Inc. and IMI Share Enthusiasm on Colorectal Cancer Research Progress

Strategic Insights

— 1 min read

Procyon Biopharma Inc. and IMI International Medical Innovations Inc. have expressed their shared excitement over the progress made in the study of ColorectAlert, a patented test for the early detection of colorectal cancer. The test involves analyzing a sample of rectal mucus taken during a routine doctor visit, which is then treated with chemicals that produce a color-change reaction identifying cancer-associated sugars. The results show a positive correlation between higher ColorectAlert values and a greater incidence of colorectal cancer. The companies are now looking forward to the outcome of a 600-patient, multicenter study conducted by renowned sites in Canada and the United States.

Key Takeaways:

  • Procyon Biopharma Inc. and IMI International Medical Innovations Inc. are collaborating on the development of ColorectAlert, a patented test for the early detection of colorectal cancer.
  • The test involves analyzing a sample of rectal mucus taken during a routine doctor visit, which is then treated with chemicals that produce a color-change reaction identifying cancer-associated sugars.
  • Previous studies on 2,000 patients have demonstrated that higher ColorectAlert values are associated with a greater incidence of colorectal cancer.
  • IMI International Medical Innovations Inc. is a company focused on predictive medicine and dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases.
  • Procyon Biopharma Inc. is a biotechnology company engaged in the discovery and development of innovative therapeutics in the fields of cancer and HIV/AIDS.
  • The companies are waiting for the outcome of a 600-patient, multicenter study conducted by renowned sites in Canada and the United States.

Statistics:

  • The study involved 2,000 patients in previous research on the correlation between ColorectAlert values and colorectal cancer incidence.
  • The newly announced study will engage 600 patients from renowned sites in Canada and the United States.
  • ColorectAlert is a patented test for the early detection of colorectal cancer.

Sources:

  • "Procyon Biopharma Inc. and IMI International Medical Innovations Inc. Share Enthusiasm on Colorectal Cancer Research Progress" by Hans J. Mader, president and chief executive officer of Procyon Biopharma Inc.
  • This article was prepared by Clinical Oncology Week editors from staff and other reports.

Read more